Pharma BD Deal Intelligence

Relmada Therapeutics, Inc. / Trigone Pharma Ltd.

2025 · Licensing/Option · Complete

Relmada Therapeutics entered an exclusive license agreement with Trigone Pharma Ltd. obtaining an exclusive, royalty-bearing, non-transferable license to Trigone's patents and know-how covering NDV-01, a fixed-dose formulation of gemcitabine and docetaxel, and products containing those compounds as sole active ingredients, together with a non-exclusive royalty-bearing license to related technology. Financial terms beyond the royalty-bearing structure were not captured from the primary filing.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2025 deals  ·  Oncology deals